FDA Approves PRECEDEX — Hospira, Inc.

# FDA Approves Hospira's PRECEDEX for Intravenous Administration Hospira, Inc. received FDA approval for PRECEDEX (dexmedetomidine hydrochloride), an intravenous sedative agent that is expected to capture significant market share in the hospital sedation market by offering an alternative to existing anesthetic protocols. The approval positions Hospira to compete in the lucrative critical care and perioperative sedation segments, potentially generating substantial revenue from widespread adoption across U.S. healthcare facilities.